---
title: "Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock"
url: "https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-10-06"
section: "Listings"
tickers: "OTC:ZVSA"
source: "https://www.sec.gov/Archives/edgar/data/1859007/000135445725000988/xslF25X02/primary_doc.xml"
summary: "The Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security."
---

By the aibio.space news desk.

Sources

- [ZyVersa Therapeutics, Inc. 25-NSE (2025-10-06)](https://www.sec.gov/Archives/edgar/data/1859007/000135445725000988/xslF25X02/primary_doc.xml)

[ZVSA](https://aibio.space/companies/zyversa-therapeutics/)

2025-10-06

# Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock

Tickers [ZVSA](https://aibio.space/companies/zyversa-therapeutics/)

The Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.

## Key facts

- **Company**: ZyVersa Therapeutics, Inc. (OTC: ZVSA)

- **News type**: Listings

- **Primary source**: [ZyVersa Therapeutics, Inc. 25-NSE (2025-10-06)](https://www.sec.gov/Archives/edgar/data/1859007/000135445725000988/xslF25X02/primary_doc.xml)

*Stone columns of a government building. Photo: The Building Envelope, CC0, via StockSnap. The picture shows the field, not the companies named.*

The Nasdaq Stock Market LLC filed a Form 25-NSE with the Securities and Exchange Commission on October 6, 2025 to remove the common stock of ZyVersa Therapeutics, Inc. from listing on the exchange.

A Form 25 is the notice filed when a security is removed from an exchange's list. The 25-NSE version is filed by the exchange rather than by the company. The [filing](https://www.sec.gov/Archives/edgar/data/1859007/000135445725000988/xslF25X02/primary_doc.xml) cites 17 CFR 240.12d2-2(b), the SEC rule under which an exchange can remove a security from listing and registration.

The notice came from a Hearings Advisor at Nasdaq, which points to a delisting that went through the exchange's hearings process. It covers ZyVersa's common stock, registered under SEC file number 001-41184. The company gives its address as 2200 N. Commerce Parkway, Suite 208, in Weston, Florida, and its phone number as (754) 231-1688.

The form is a one-page notice with no narrative about the removal.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ZVSA

ZyVersa Therapeutics, Inc.

OTC · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nasdaq files Form 25 to delist ZyVersa Therapeutics common stock", 2025-10-06, https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/